Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
26 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Alitair Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Alitair Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Alitair Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Alitair Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Alitair Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Alitair Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Alitair Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Alitair Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Alitair Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Alitair Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Alitair Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alitair Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Alitair Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Alitair Pharmaceuticals, Inc. Snapshot 4 Alitair Pharmaceuticals, Inc. Overview 4 Key Information 4 Key Facts 4 Alitair Pharmaceuticals, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Alitair Pharmaceuticals, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pipeline Products - Partnered Products 9 Partnered Products/Combination Treatment Modalities 10 Alitair Pharmaceuticals, Inc. - Pipeline Products Glance 11 Alitair Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Alitair Pharmaceuticals, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Alitair Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 13 Unknown Products/Combination Treatment Modalities 13 Alitair Pharmaceuticals, Inc. - Drug Profiles 14 erdosteine 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 ALT-07 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 ALT-09 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 benzonatate polacrilex 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Alitair Pharmaceuticals, Inc. - Pipeline Analysis 19 Alitair Pharmaceuticals, Inc. - Pipeline Products by Target 19 Alitair Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 20 Alitair Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 21 Alitair Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 22 Alitair Pharmaceuticals, Inc. - Recent Pipeline Updates 23 Alitair Pharmaceuticals, Inc. - Locations And Subsidiaries 24 Head Office 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables Alitair Pharmaceuticals, Inc., Key Information 4 Alitair Pharmaceuticals, Inc., Key Facts 4 Alitair Pharmaceuticals, Inc. - Pipeline by Indication, 2014 6 Alitair Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 7 Alitair Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 8 Alitair Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 9 Alitair Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 10 Alitair Pharmaceuticals, Inc. - Phase II, 2014 11 Alitair Pharmaceuticals, Inc. - Preclinical, 2014 12 Alitair Pharmaceuticals, Inc. - Unknown, 2014 13 Alitair Pharmaceuticals, Inc. - Pipeline by Target, 2014 19 Alitair Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 20 Alitair Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 21 Alitair Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 22 Alitair Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 23
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.